

BioWisdom Appoints Chief Technology Officer

Submitted by: BioWisdom Ltd

Tuesday, 22 July 2003

(22nd July 2003, Cambridge, UK) Leading provider of Drug Discovery Ontologies BioWisdom are pleased to announce the appointment of Dr Steve Gardner as Chief Technology Officer. Steve will be responsible for the technical strategy supporting BioWisdom's Discovery Ontology products.

Throughout his career, Steve has held several high profile roles, the last being SVP & CTO of Viaken Systems, Inc., which was later acquired by VSA Corp. Prior to Viaken, Steve was Founder and CEO of Synomics Ltd, and Worldwide Director of Research Informatics for Astra AB.

"BioWisdom produces very high quality, expertly annotated ontologies focussed on drug discovery. These tools have wide applications across the research, development and commercial processes," said Gardner. "I am very excited about joining the BioWisdom senior executive team and look forward to helping the company develop its excellent set of ontology based products and services."

"We are delighted to bring Steve on board," said Gordon Baxter, CEO of BioWisdom. "Steve is a well-known and respected Informatics Specialist. He has gained a wealth of experience building world-class companies, teams and products primarily for the life science industry both in Europe and the USA. Steve has designed, built and brought to market a number of innovative and commercially successful informatics products to support drug discovery."

About BioWisdom

BioWisdom Ltd., headquartered in Cambridge UK, established in September 2000, is a biomedical informatics company developing systems which help R&D professionals to access critical information and to assist them in the discovery and development of novel drug therapies. BioWisdom produces powerful life science ontologies, which describe important discovery concepts such as proteins, tissues, diseases, compounds and the inter-relationships between them. BioWisdom's Discovery Ontologies deliver improved searching, integration and navigation through complex research information.

-ENDS-

For further information, please contact:

Gordon Smith Baxter, CEO
BioWisdom Ltd
Tel: +44 (0)1223 492100
email: gordon.baxter@biowisdom.com
<http://www.biowisdom.com>